Published in PLoS One on April 08, 2009
Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer (2010) 1.92
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med (2009) 1.59
Hybrid models of tumor growth. Wiley Interdiscip Rev Syst Biol Med (2010) 1.52
Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol (2015) 1.25
Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med (2010) 1.06
Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol (2013) 0.99
The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comput Biol (2009) 0.96
Theoretical models for coronary vascular biomechanics: progress & challenges. Prog Biophys Mol Biol (2010) 0.96
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol (2011) 0.94
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol (2010) 0.93
Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS One (2010) 0.92
Inhibitory effects of polysaccharide extract from Spirulina platensis on corneal neovascularization. Mol Vis (2009) 0.90
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics (2009) 0.90
Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One (2012) 0.90
Computational models of VEGF-associated angiogenic processes in cancer. Math Med Biol (2011) 0.87
Cardiac models in drug discovery and development: a review. Crit Rev Biomed Eng (2011) 0.84
A two-compartment model of VEGF distribution in the mouse. PLoS One (2011) 0.84
Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: a mathematical model. Bull Math Biol (2012) 0.83
Involvement of tumor macrophage HIFs in chemotherapy effectiveness: mathematical modeling of oxygen, pH, and glutathione. PLoS One (2014) 0.82
Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.77
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models. Methods Enzymol (2009) 0.77
Molecular mechanism matters: Benefits of mechanistic computational models for drug development. Pharmacol Res (2015) 0.77
Alterations of plasma nitric oxide, vascular endothelial growth factor, and soluble form of its receptor (sFlt-1) after resistance exercise: An experimental study. Adv Biomed Res (2014) 0.75
A computational analysis of in vivo VEGFR activation by multiple co-expressed ligands. PLoS Comput Biol (2017) 0.75
A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF165b in peripheral arterial disease in human and mouse. Sci Rep (2016) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 10.32
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry (1982) 6.87
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem (1994) 6.18
Lymphangiogenesis in development and human disease. Nature (2005) 5.93
Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol (1985) (2000) 5.24
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A (1993) 5.02
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol (2005) 4.03
Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol (2006) 3.95
Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol (2006) 3.49
Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun (1996) 3.33
Flow through interstitium and other fibrous matrices. Q J Exp Physiol (1987) 3.20
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays (1998) 3.04
The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) (2005) 2.89
Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol (2007) 2.69
Capillary supply of the quadriceps femoris muscle of man: adaptive response to exercise. J Physiol (1977) 2.65
Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest (1968) 2.60
Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn (2001) 2.53
Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res (2004) 2.52
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry (1989) 2.49
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol (2005) 2.34
VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans (2003) 2.31
Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol (2005) 2.28
Vascular endothelial growth factor localization in the adult. Am J Pathol (2006) 2.20
Physiology of fibronectin. Annu Rev Med (1984) 2.17
Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem (2001) 2.15
Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem (1996) 2.12
Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res (2006) 2.08
Myonuclear domains in muscle adaptation and disease. Muscle Nerve (1999) 2.07
VIP-Man: an image-based whole-body adult male model constructed from color photographs of the Visible Human Project for multi-particle Monte Carlo calculations. Health Phys (2000) 1.99
Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem (2005) 1.90
VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood (2006) 1.87
Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem (2004) 1.87
Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A (2000) 1.84
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol (2008) 1.82
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res (2003) 1.82
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res (2004) 1.79
Skeletal muscle capillaries in diabetics. A quantitative analysis. Circulation (1970) 1.79
Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic (2006) 1.78
Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem (2007) 1.73
Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene (1999) 1.71
Interstitial fluid volume: local regulatory mechanisms. Physiol Rev (1981) 1.70
Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) (2002) 1.67
Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood (2008) 1.66
Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest (2000) 1.66
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther (2002) 1.63
The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci (2006) 1.63
The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem (2000) 1.60
Density and hydration of fresh and fixed human skeletal muscle. J Biomech (2004) 1.59
Vascular recruitment in skeletal muscle during exercise and hyperinsulinemia assessed by contrast ultrasound. Am J Physiol Endocrinol Metab (2002) 1.56
Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci U S A (1991) 1.55
VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem (2005) 1.53
Transport of large molecules from plasma to interstitial fluid and lymph in dogs. Am J Physiol (1970) 1.52
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest (2000) 1.50
Roles for VEGF in the adult. Microvasc Res (2007) 1.48
A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock (2008) 1.47
Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res (2006) 1.46
Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem (1997) 1.41
Systems biology of vascular endothelial growth factors. Microcirculation (2008) 1.41
Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem (2000) 1.41
Correlation of endothelial cell shape and wall shear stress in a stenosed dog aorta. Arteriosclerosis (1986) 1.41
Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int (2005) 1.41
Inter-society consensus for the management of peripheral arterial disease. Int Angiol (2007) 1.39
Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett (2006) 1.35
Integrated approach to designing growth factor delivery systems. FASEB J (2007) 1.35
Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol (2003) 1.33
Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology (2004) 1.33
VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res (2007) 1.32
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer (2005) 1.28
Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med (2007) 1.28
Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res (2007) 1.28
Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem (2005) 1.24
Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects. J Cell Physiol (1991) 1.23
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 1.23
Circulating plasma VEGF response to exercise in sedentary and endurance-trained men. J Appl Physiol (1985) (2003) 1.22
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol (2006) 1.22
Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med (2002) 1.22
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol (2008) 1.22
Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol (2006) 1.21
The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol (2003) 1.21
Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol (2007) 1.20
VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol (1985) (2006) 1.20
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther (2003) 1.18
Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell (2007) 1.18
Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem (2007) 1.18
Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Comput Biol (2006) 1.17
Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry (2006) 1.16
Lower skeletal muscle capillarization and VEGF expression in aged vs. young men. J Appl Physiol (1985) (2005) 1.16
Flow and composition of leg lymph in normal men during venous stasis, muscular activity and local hyperthermia. Acta Physiol Scand (1977) 1.16
Acute resistance exercise increases skeletal muscle angiogenic growth factor expression. Acta Physiol (Oxf) (2007) 1.15
No difference in the skeletal muscle angiogenic response to aerobic exercise training between young and aged men. J Physiol (2007) 1.14
Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst (2013) 1.75
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med (2009) 1.59
A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem (2004) 1.51
A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol (2008) 1.50
Temporal and spatial variations of cell-free layer width in arterioles. Am J Physiol Heart Circ Physiol (2007) 1.46
Systems biology of vascular endothelial growth factors. Microcirculation (2008) 1.41
Computational fluid dynamic simulation of aggregation of deformable cells in a shear flow. J Biomech Eng (2005) 1.40
Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol (2003) 1.33
Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol (2011) 1.32
Multiscale models of angiogenesis. IEEE Eng Med Biol Mag (2009) 1.26
Effects of erythrocyte deformability and aggregation on the cell free layer and apparent viscosity of microscopic blood flows. Microvasc Res (2009) 1.24
Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res (2010) 1.22
Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol (2008) 1.21
Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol (2006) 1.21
Effect of aggregation and shear rate on the dispersion of red blood cells flowing in venules. Am J Physiol Heart Circ Physiol (2002) 1.20
VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol (1985) (2006) 1.20
A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1 alpha. J Cell Sci (2006) 1.20
Blood flow and cell-free layer in microvessels. Microcirculation (2010) 1.19
A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem (2007) 1.18
Experimental and theoretical studies of oxygen gradients in rat pial microvessels. J Cereb Blood Flow Metab (2008) 1.18
Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys Chem (2007) 1.18
Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Comput Biol (2006) 1.17
A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A (2008) 1.16
Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. Antioxid Redox Signal (2008) 1.16
Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J Theor Biol (2005) 1.16
Theoretical analysis of biochemical pathways of nitric oxide release from vascular endothelial cells. Free Radic Biol Med (2006) 1.15
Red blood cell aggregation and dissociation in shear flows simulated by lattice Boltzmann method. J Biomech (2007) 1.14
Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J (2012) 1.14
Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res (2010) 1.14
Effect of outer hair cell piezoelectricity on high-frequency receptor potentials. J Acoust Soc Am (2003) 1.13
Erythrocyte consumption of nitric oxide in presence and absence of plasma-based hemoglobin. Am J Physiol Heart Circ Physiol (2002) 1.13
Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am J Physiol Heart Circ Physiol (2005) 1.11
Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst Biol (2009) 1.10
Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol (2006) 1.10
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. J Appl Physiol (1985) (2004) 1.07
Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdiscip Rev Syst Biol Med (2010) 1.06
A computer-based method for determination of the cell-free layer width in microcirculation. Microcirculation (2006) 1.06
Wall shear stress differentially affects NO level in arterioles for volume expanders and Hb-based O2 carriers. Microvasc Res (2003) 1.05
Module-based multiscale simulation of angiogenesis in skeletal muscle. Theor Biol Med Model (2011) 1.04
Nitric oxide from nitrite reduction by hemoglobin in the plasma and erythrocytes. Nitric Oxide (2007) 1.03
Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. Am J Physiol Heart Circ Physiol (2002) 1.03
Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties. Biochem Biophys Res Commun (2007) 1.03
Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann Biomed Eng (2007) 1.03
A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Ann Biomed Eng (2004) 1.02
Endothelial cell-dependent regulation of arteriogenesis. Circ Res (2013) 1.00
A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. J Theor Biol (2006) 1.00
Relationship between erythrocyte aggregate size and flow rate in skeletal muscle venules. Am J Physiol Heart Circ Physiol (2003) 1.00
Calculations of oxygen transport by red blood cells and hemoglobin solutions in capillaries. Artif Cells Blood Substit Immobil Biotechnol (2002) 1.00
Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. Am J Physiol Heart Circ Physiol (2004) 1.00
Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol (2013) 0.99
A computational model of oxygen delivery by hemoglobin-based oxygen carriers in three-dimensional microvascular networks. J Theor Biol (2007) 0.98
Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol (2011) 0.98
Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. Biochim Biophys Acta (2007) 0.97
An immersed boundary lattice Boltzmann approach to simulate deformable liquid capsules and its application to microscopic blood flows. Phys Biol (2007) 0.97
Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Am J Physiol Heart Circ Physiol (2007) 0.97
Aggregate formation of erythrocytes in postcapillary venules. Am J Physiol Heart Circ Physiol (2004) 0.96
Selective activation of sphingosine 1-phosphate receptors 1 and 3 promotes local microvascular network growth. Tissue Eng Part A (2010) 0.96
The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling. PLoS Comput Biol (2009) 0.96
Theoretical models for coronary vascular biomechanics: progress & challenges. Prog Biophys Mol Biol (2010) 0.96
Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia (2013) 0.96
Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng (2012) 0.94
A theoretical model of nitric oxide transport in arterioles: frequency- vs. amplitude-dependent control of cGMP formation. Am J Physiol Heart Circ Physiol (2003) 0.94
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One (2013) 0.94
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis. BMC Syst Biol (2011) 0.94
Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation. Int J Biochem Cell Biol (2011) 0.94
Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer (2010) 0.93
Computational modeling of interacting VEGF and soluble VEGF receptor concentration gradients. Front Physiol (2011) 0.93
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Physiol Heart Circ Physiol (2010) 0.93
Hypotonic swelling of salicylate-treated cochlear outer hair cells. Hear Res (2007) 0.93
Effect of erythrocyte aggregation at normal human levels on functional capillary density in rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol (2005) 0.92
Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PLoS One (2010) 0.92
Vascular smooth muscle NO exposure from intraerythrocytic SNOHb: a mathematical model. Antioxid Redox Signal (2007) 0.92
Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med (2014) 0.92
Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem (2011) 0.91
An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator. Biotechnol Bioeng (2002) 0.90
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics (2009) 0.90
Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Physiol Heart Circ Physiol (2013) 0.90
A model of nitric oxide capillary exchange. Microcirculation (2003) 0.90
Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines. J Cell Biochem (2008) 0.90
Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One (2012) 0.90
Blood-plasma separation in Y-shaped bifurcating microfluidic channels: a dissipative particle dynamics simulation study. Phys Biol (2012) 0.89
Anti-angiogenic peptides identified in thrombospondin type I domains. Biochem Biophys Res Commun (2007) 0.89
Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochim Biophys Acta (2005) 0.88
Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. Int J Biochem Cell Biol (2007) 0.87